

**AMENDMENTS TO THE SPECIFICATION**

***Please replace the paragraph on page 9, lines 23-24, with the following paragraph marked-up to show changes made.***

Fig. 4 is a graph obtained by monitoring time-dependent NK4 secretion of OMEC (epithelial cells of the oral cavity mucous membrane) into which Ad-NK4 is introduced.

***Please replace the paragraph on page 9, lines 27-29, with the following paragraph marked-up to show changes made.***

Fig. 6 is a graph showing an effect of NK4 secreted from OMEC into which Ad-NK4 is introduced, on inhibition of invasion of pancreatic cancer cells.

***Please replace the paragraph on page 12, lines 18-22, with the following paragraph marked-up to show changes made.***

Substitution or other operations may be applied by the known method such as ODA-LA PCR method, gapped duplex method or Kunkel method, or a method similar to these methods using PCR and known kits, for example Mutan<sup>TM</sup>-superExpress Km (site directed mutagenesis kit) (Takara Shuzo Co.) or Mutan<sup>TM</sup>-K (oligonucleotide mutagenesis kit) (Takara Shuzo Co.).

***Please replace the paragraph on page 22, lines 23-28, with the following paragraph marked-up to show changes made.***

A mesh sheet of a surgical suture made of a biodegradable polymer material is preferable for the mesh sheet of the biodegradable resin. Particularly, polyglycolic acid is preferable as the biodegradable polymer in the present invention, and an example of the mesh sheet of the biodegradable resin is knitted-type VICRYL<sup>TM</sup> (polyglactin 910) mesh; Ethicon, Inc., New Jersey.

***Finally, please replace the paragraph on page 30, line 13 to page 31, line 1, with the following paragraph marked-up to show changes made.***

mRNA was isolated from subcutaneous tissue cells of Wister rat or OMEC using ISOGEN-LS (Nippon Gene Co., Ltd., Toyama, Japan), and the mRNA was used for RT-PCR(reverse transcription/polymerase chain reaction) to isolate NK4 cDNA. Specifically, 0.5 µl of mRNA solution (150 ng of mRNA), and 5 µl of 10×RT-PCR solution (500 mM KCl, 100 mM Tris-HCl (pH 9.0), 1% Triton X-100, 15 mM MgCl<sub>2</sub>), 4 µl of dNTP (2.5 mM), 2 µl of primer 1 (10 mM), 2 µl of primer 2 (10 mM), 0.5 µl of Taq polymerase (Takara), 0.5 µl of RNasin (Promega), 0.5 µl of reverse transcriptase (Takara) and 35.2 µl of DEPC-treated H<sub>2</sub>O were mixed. The reverse transcription reaction was performed at 42°C for 30 minutes and at 95°C for 5 minutes, and a cycle of 94°C for 30 seconds, 55°C for 1 minute and 72°C for 1 minute was repeated 40 times, followed by a reaction at 72°C for 7 minutes to obtain NK4 cDNA. NK4 cDNA thus obtained was cloned into pCRII<sup>TM</sup> vector using TA Cloning Kit (Invitrogen) to obtain pCRII/NK4. The primer used was the DNA fragment represented by SEQ ID NO:5 or SEQ ID NO: 6.